Tumor lymphocyte infiltration is associated with favorable prognosis in early triple-negative and human epidermal growth factor receptor type 2 (HER2)-positive breast cancer phenotypes [1–4] and may influence the response to systemic therapies [3–6]. Here, ERBB2 is linked to breast carcinoma.